Stealth BioTherapeutics Corp logo
Stealth BioTherapeutics Corp MITO

Annual report 2021
added 12-23-2023

report update icon

Stealth BioTherapeutics Corp Revenue 2011-2026 | MITO

Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.

Traditionally defined as follows:
Revenue = Price * Quantity of products

Revenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]

This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.

Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.

Annual Revenue Stealth BioTherapeutics Corp

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
- - 21.1 M - - - - - - - -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
21.1 M 21.1 M 21.1 M

References

  1. Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).

Revenue of other stocks in the Biotechnology industry

Issuer Revenue Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
238 M - 2.43 % $ 254 M germanyGermany
Grifols, S.A. Grifols, S.A.
GRFS
7.21 B $ 8.24 -0.12 % $ 6.83 B spainSpain
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
720 M $ 229.25 0.44 % $ 5 B danmarkDanmark
I-Mab I-Mab
IMAB
88 M - - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
6.07 B - - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
70.9 M - 2.54 % $ 160 B franceFrance
Midatech Pharma plc Midatech Pharma plc
MTP
381 K - -18.52 % $ 27.3 M britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
12.1 K - -1.52 % $ 24.7 M usaUSA
AbbVie AbbVie
ABBV
16.6 B $ 208.84 -2.86 % $ 369 B usaUSA
AbCellera Biologics AbCellera Biologics
ABCL
75.1 M $ 3.52 0.28 % $ 1.05 B canadaCanada
Acorda Therapeutics Acorda Therapeutics
ACOR
118 M - -24.86 % $ 820 K usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
1 M - - $ 86.2 M usaUSA
Advaxis Advaxis
ADXS
13 K - -9.65 % $ 45.9 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
9.59 M - 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
130 K - -10.17 % $ 12.2 K usaUSA
AIkido Pharma AIkido Pharma
AIKI
123 M - 1.93 % $ 17.4 M usaUSA
Agenus Agenus
AGEN
114 M $ 3.33 -2.06 % $ 99 M usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
886 K - - $ 1.01 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
325 K - - $ 26.5 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
1.08 B - - - russiaRussia
Alpine Immune Sciences Alpine Immune Sciences
ALPN
30.1 M - - $ 2.17 B usaUSA
Adaptive Biotechnologies Corporation Adaptive Biotechnologies Corporation
ADPT
277 M $ 14.81 2.63 % $ 2.25 B usaUSA
Altimmune Altimmune
ALT
41 K $ 3.34 7.05 % $ 294 M usaUSA
BioNTech SE BioNTech SE
BNTX
482 M $ 91.18 1.97 % $ 27.2 B germanyGermany
Amgen Amgen
AMGN
36.8 B $ 347.94 -1.51 % $ 187 B usaUSA
ANI Pharmaceuticals ANI Pharmaceuticals
ANIP
614 M $ 74.21 -2.3 % $ 1.43 B usaUSA
Aravive Aravive
ARAV
9.14 M - -13.39 % $ 1.45 M usaUSA
Arcturus Therapeutics Holdings Arcturus Therapeutics Holdings
ARCT
82 M $ 8.03 2.29 % $ 220 M israelIsrael
Aurinia Pharmaceuticals Aurinia Pharmaceuticals
AUPH
77.1 M $ 15.61 0.9 % $ 2.1 B canadaCanada
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
75.4 M $ 1.41 2.17 % $ 375 M britainBritain
Aptinyx Aptinyx
APTX
1 M - -39.0 % $ 4.57 M usaUSA
Aytu BioScience Aytu BioScience
AYTU
66.4 M $ 2.68 1.52 % $ 16.8 M usaUSA
CureVac N.V. CureVac N.V.
CVAC
48.9 M - - $ 867 M germanyGermany
AstraZeneca PLC AstraZeneca PLC
AZN
58.7 B - - $ 96.9 B britainBritain
Burford Capital Limited Burford Capital Limited
BUR
330 M $ 4.14 -2.59 % $ 683 M britainBritain
Avenue Therapeutics Avenue Therapeutics
ATXI
1.4 M - -52.27 % $ 4.45 M usaUSA
Atea Pharmaceuticals Atea Pharmaceuticals
AVIR
351 M $ 5.76 1.95 % $ 469 M usaUSA
BioCryst Pharmaceuticals BioCryst Pharmaceuticals
BCRX
451 M $ 9.02 -3.84 % $ 1.86 B usaUSA
Axon Enterprise Axon Enterprise
AXON
2.08 B $ 412.81 -2.54 % $ 31.3 B usaUSA
Alnylam Pharmaceuticals Alnylam Pharmaceuticals
ALNY
3.71 B $ 318.85 -3.01 % $ 41.8 B usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
692 K - - $ 7.46 M israelIsrael